Abstract
Objective To explore the efficacy and safety of high-dose methotrexate (MTX) and L-asparaginase (L-Asp) for the treatment of adult patients with high risk Ph- acute lymphoblastic leukemia (ALL). Methods Five adult patients with high risk Ph- ALL were treated with several courses of MTX (3-5 g/m2 by continually intravenous drip for 24 h) and L-Asp (8 000-10 000 U/time, once a day, 10 times for one cycle). Results Five patients were disease-free survival, their survival time was 60-96 months and the median survival time was 73 months. The chemotherapy-related bone marrow depression was mild. No obvious liver and kidney damage, severe allergic reaction and pancreatitis were observed. Conclusion High-dose MTX and L-Asp are effective and well tolerated, and may contribute to long-term survival of adult patients with high risk Ph- ALL. Key words: Leukemia, lymphocytic, acute; Methotrexate; L-asparaginase; Long-term survival
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
